Navigation Links
Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Date:10/22/2009

PHILADELPHIA October 22, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. Specifically, the overall rate and extent of exposure to d-amphetamine, the active medication in Vyvanse, was similar in healthy adults whether they received the drug as a solution through the nose or orally as a capsule. These findings, which were recently presented at a major psychiatric meeting, reflect the ongoing efforts of Shire to further understand the abuse potential of Vyvanse.

"This research is important because the route of administration of a drug may affect the rate and extent of absorption, which in turn may affect the risk of abuse. However, in this study, absorption of Vyvanse through the nose did not result in a rapid rise in d-amphetamine levels," said Patrick Martin, MD, Vice President, Global Clinical Pharmacology and Pharmacokinetics at Shire. "In this study, exposure to d-amphetamine did not differ when Vyvanse was administered orally or intranasally. While the results of this study are important, it is not accurate to say or imply that Vyvanse cannot be abused."

Vyvanse is indicated for oral administration only, and should not be administered intranasally.

About Vyvanse Vyvanse, which is approved to treat ADHD in children aged 6 to 12 years and in adults, is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. ADHD stimulant products are classified as schedule II controlled substances because a high potential for abuse exists.

About the Study This open-label, two-period, crossover study compared the pharmacokinetics of d-amphetamine, the active medication derived from Vyvanse, in 18 healthy men after single administration through nasal and oral routes. The primary objectives of the study were to determine whether Vyvanse is absorbed after intranasal delivery and to assess the extent of absorption and conversion to d-amphetamine, specifically whether administration through the nose would alter the rate and extent of absorption. A secondary study objective was to evaluate the safety of Vyvanse administered as a single oral dose and a single intranasal dose.

In the study, investigators randomly assigned participants to receive a single nasal or oral dose of Vyvanse 50 mg, then, at least seven days later, the subjects received the opposite regimen. Results showed that the rate and extent of d-amphetamine exposure were similar in the healthy participants who received a single 50-mg dose of Vyvanse either through the nose via a solution formulation or orally in capsule form. Specifically, the median time to maximum plasma concentration of d-amphetamine was five hours after oral administration of Vyvanse and four hours after intranasal administration of Vyvanse. Maximum plasma concentration for intranasal administration and oral administration of Vyvanse were similar (35.9 ng/mL versus 37.6 ng/mL, respectively).

In this study, treatment-emergent adverse events were mild to moderate in severity and consistent with known effects of amphetamine. The most common adverse events with an incidence greater than 5 percent among subjects administered Vyvanse by intranasal administration were: tachycardia (two of 18 subjects), dry mouth (two of 18 subjects), and feeling jittery (two of 18 subjects), and for oral administration: anorexia (four of 18 subjects). Adverse events were more common after intranasal administration, reported by 38.9 percent of participants (seven of 18), compared with 27.8 percent of participants (five of 18) after oral administration.

Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.


'/>"/>

Contact: Matthew Cabrey, Shire
484-595-8248
Porter Novelli
Source:Eurekalert

Related medicine news :

1. VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD
2. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
3. VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
4. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
5. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
6. FDA approves additional dosage strengths of Vyvanse
7. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
8. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
9. Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories (West Caldwell, NJ) to Market Ergocalciferol (Vitamin D) Capsules
10. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
11. Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a ... Missouri. The company has achieved record-breaking sales for over 30 consecutive years and ... 12 months. , The upcoming year offers excitement and growth at HDIS, following the ...
(Date:7/25/2017)... PALM SPRINGS, California (PRWEB) , ... July 25, 2017 , ... ... don't involve cranking up the air conditioner — think homemade gourmet ice cream, sparkling ... up inside a gift shop featuring fun mugs, journals, and other must-have knick knacks. ...
(Date:7/25/2017)... Deerfield Beach, Florida (PRWEB) , ... July 25, ... ... newest employee, Jennifer Haller, to the sales department joining as Regional Account Manager ... maintain relationships with contracted customers in the liquidation of their obsolete medical assets. ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist ... partnership to provide the Pharmacist eCare Plan to Computer-Rx pharmacies through ... with the ability to develop the Pharmacist eCare Plan, a shared document detailing ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance Group, a ... communities across North Carolina, is launching a charity event in conjunction with the ... the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy Network (BCAN) ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... 2017  Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited to host ... at the Bonaventure Resort & Spa in Weston, Florida ... Luncheon ... Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
Breaking Medicine Technology: